Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Baitai Biological Pharmaceutical
Beijing, Beijing, China
- Ownership
- Private
- Employees
- ~500
- Development stage
- Other
01
Overview
Beijing Baitai Biological Pharmaceutical has successfully commercialized Nimotuzumab (Taixinqi) for nasopharyngeal carcinoma in China. The drug is noted for its high specificity and lower skin toxicity compared to other EGFR inhibitors. The company is currently conducting multiple Phase 3 trials to expand Nimotuzumab's indications and is advancing Itolizumab for autoimmune conditions.
- Therapeutic areas
- OncologyImmunologyDermatology
- Modalities
- Monoclonal antibodyRecombinant proteinBiologic
- Industry
- Biotech
02
Partnerships
Center of Molecular Immunology (CIM)Biocon
Beyond the preview
Go deeper on Beijing Baitai Biological Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beijing Baitai Biological Pharmaceutical.